Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma

Journal of Surgical Oncology

Volumn 90, Issue 2, 2005, Pages 51-56

  Reichman, Trevor W ^a   Cracchiolo, Bernadette ^a   Sama, Jahir ^a   Bryan, Margarette ^a   Harrison, Jonathan ^a   Pliner, Lillian ^a   Harrison, Lawrence E ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Carcinomatosis; IHCP; Ovarian cancer

Indexed keywords

CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DATA BASE; FEMALE; HUMAN; HYPERTHERMIC THERAPY; INTRAOPERATIVE HYPERTHERMIC CHEMOPERFUSION THERAPY; INTRAOPERATIVE PERIOD; OUTCOMES RESEARCH; OVARY CARCINOMA; PATIENT SELECTION; PERITONEAL CANCER INDEX; PERITONEUM CANCER; PREDICTION; PRIORITY JOURNAL; SAFETY; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; INTRAOPERATIVE CARE; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PATIENT SELECTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17844407135     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20243     Document Type: Article

References (21)

1. Bristow RE, Tomacruz RS, Armstrong DK, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20:1248-1259.
2. Vasey PA: Resistance to chemotherapy in advanced ovarian cancer: Mechanisms and current strategies. Br J Cancer 2003;89:23-28.
3. Sugarbaker PH: Management of peritoneal-surface malignancy: The surgeon's role. Langenbecks Arch Surg 1999;384:576-587.
4. Verwaal VJ, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-3743.
5. Ceelen WP, Hesse U, de Hemptinne B, et al.: Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg 2000;87:1006-1015.
6. Feldman AL, Libutti SK, Pingpank JF, et al.: Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560-4567.
7. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004; 22:3284-3292.
8. Cannistra SA: Cancer of the ovary. N Eng J Med 2004;351:2519-2529.
9. Morgan RJ, Alvarez RD, Armstrong DK, et al.: Ovarian Cancer: Clinical Practice guidelines. J Nat Com Cancer Network 2004;2: 526-547.
10. Alberts DS, Liu PY, Hannigan EV, et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Eng J Med 1996;335:1950-1955.
11. Yen MS, Juang CM, Lai CR, et al.: Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 2001;72:55-60.
12. Polyzos A, Tsavaris N, Giannikos L, et al.: A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 1999;56:291-296.
13. Markman M: Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncology 2003;4:277-283.
14. Hager ED, Dziambor H, Hohmann D, et al.: Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynaecol Obstet 2001;11:57-63.
15. Masuda H, Tanaka T, Matsushima S: Hyperthermic enhancement of cisplatin-induced generation of active oxygen radicals in a cell-free system. Anticancer Res 1998;18:1473-1477.
16. Los G, Pinedo HM, van Vugt MJ: Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69:235-241.
17. van de Vaart PJ, van der Vange N, Zoetmulder FA, et al.: Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148-154.
18. Deraco M, Rossi CR, Pennacchioli E, et al.: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: A phase II clinical study. Tumori 2001;87:120-126.
19. Look M, Chang D, Sugarbaker PH: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynaecol Obstet 2003;13:764-770.
20. Piso P Dahlke MH, Loss M, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Onc 2004;2: 21-28.
21. Boente MP, Chi DS, Hoskins WJ: The role of surgery in the management of ovarian cancer: Primary and interval cytoreductive surgery. Semin Oncol 1998;25:326-334.